The best drug development decisions come from rigorous science, evidence you can trace, and a genuine wish to get a working medicine to the patients waiting for it. Speed saves lives. Evidence saves time.
That is what more than twenty years in drug development taught me — as a regulatory reviewer, a pharma executive and now an advisor.
Pharm·ology was founded in 2025 by Christoffer Wenzel Tornøe.

BACKGROUND
I started at the U.S. Food and Drug Administration as a pharmacometrics reviewer. Inside the agency, I learned regulatory science as it is actually practiced: what a review weighs, why a program gets a question instead of an approval, and how much of the reasoning never makes it into the public summary.
More than a decade at Novo Nordisk followed, most recently as Corporate Project Vice President for the Obesity and MASH portfolio — accelerating clinical development timelines, leading strategic execution for the global obesity franchise, and chairing the Inversago Pharma acquisition.
The training underneath both is quantitative: a master's in chemical engineering, a PhD in applied statistics focused on pharmacokinetic and pharmacodynamic modeling, and published research in clinical pharmacology.
I have sat in the chair asking the question, and in the chair writing the answer. Most of what the QD [Quantify Decisions] drug development platform extracts is there because I know what it costs not to have it.
TRACK RECORD
Last patient last visit to submission in 12 days — instead of the usual six months, by restructuring the work around precedent from comparable submissions.
Broader labels without new trials — re-using existing trial data, based on what each agency had already accepted, to secure new dose regimens and patient populations.
Differentiation as a quantified claim — benchmarking an asset attribute by attribute against its competitors, so the value story held up with KOLs, regulators and the board.
Pharm·ology ApS · contact@pharmology.dk · CVR 45557898

WHY PHARM·OLOGY?